Science and Technology



Publications

Diseased and Aging Skin

  1. IMS NPA Plus.   April 2003.
  2. 2005 ASAPS Statistics.   Accessed at www.surgery.org/download/2005trends.pdf .
  3. Executive Summary: Global market for dermal fillers 2005-2011.  Aesthetic Buyers Guide.   2006 Medical Insight, Inc., available at http://www.miinews.com.

Antimicrobial Peptide References

  1. Gallo R, Nizet V.  Endogenous production of antimicrobial peptides in innate immunity and human disease.  Curr Allergy and Asthma Rep. 2003:3:402-409.
  2. Guarna MM, Coulson R and Rubinchik E.   Anti-inflammatory activity of cationic peptides: Application to the treatment of acne vulgaris.   FEMS Microbiol Lett. 2006;257:1-6.
  3. Jenssen H, Hamill P and Hancock R.  Peptide antimicrobial agents.  Clin Microbiol Rev 2006:19:491-511.
  4. Sader H, Fedler K, Rennie R, Stevens S, Jones R.  Omiganan pentahydrochloride (MBI 226), a topical 12-amino acid cationic peptide: Spectrum of antimicrobial activity and measurements of bactericidal activity.   Antimicrob Agents Chemother . 2004;48:3112-3118.

Chitosan References

  1. Borzacchielo A, Ambrosio, L, Netti, P, Nicolais L, Peniche C, Gallardo A, San Roman J. Chitosan-based hydrogels: synthesis and characterization.   J Mat Sci. 2001;861-864
  2. Cattaneo M, Demierre MF.  Biodegradable chitosan for topical delivery of retinoic acid, Drug Delivery Technologies. 2001:1(1)

Ionic Contra Viral Therapy (ICVT) References

  1. Hartley C, et al. Ionic contra-viral therapy (ICVT); a new approach to the treatment of DNA virus infections.  Arch Virol 2006:in Press.
  2. Henderson Morley web site: http://www.hendersonmorley.com/main/icvt_mechanism.html Accessed 10/13/06.

Omiganan Publications and Presentations

  1. Friedland H, Rubinchik E, Ruiz de Algara T, McDonald-Jones G, Labbe S, Pasetka C, Erfle D.  Efficacy of MBI-226 antimicrobial peptide in two animal models of skin colonization.  39 th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 26-29, 1999; San Francisco, USA. Poster-1013.
  2. McNicol P, Friedland H, Fraser J, and Krieger T. MBI 226 Antimicrobial peptide prevents colonization of intravenous catheters. 39 th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 26-29, 1999; San Francisco, USA. Poster-1674.
  3. McNicol P, Workman L, Lopez J, Martin W, Schneider L, Wong E, Friedland D.  Cationic antimicrobial peptide bactolysins are active against antibiotic-sensitive and -resistant organisms implicated in ophthalmic infections and are non-irritating in a rabbit eye model. 39 th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 26-29, 1999; San Francisco, USA. Poster-1814.  (Note: MBI 226 is called Bactolysin A in this publication)
  4. McNicol P, Rubinchik E, Pasetka C, Barger R, Lopez J, Friedland H.  MBI 594AN is active against acne vulgaris organisms, does not induce resistance and has anti-inflammatory activity in vivo .  41 st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Dec. 16-19, 2001; Chicago, USA.  Poster-349.
  5. Dugourd D, Pasetka C, Erfle D, Rubinchik E, Lee K, Friedland H, McNicol P.  MBI 226 antimicrobial peptide interacts with gram-positive and gram-negative cell membranes.  102 nd Annual meeting of American Society for Microbiology; May 18-23, 2002; Salt Lake City, USA.  Poster-A-46.
  6. Dugourd D, Pasetka C, Erfle D, Rubinchik E, Guarna M, McNicol P, Friedland H.  MBI 226 antimicrobial peptide inhibits Staphylococcus aureus macromolecular synthesis.  102 nd Annual meeting of American Society for Microbiology; May 18-23, 2002; Salt Lake City, USA.  Poster-A-47.
  7. Brown S, Traczewski M. Omiganan pentahydrochloride (MBI 226): In-vitro spectrum and effects of environmental variation on MICs.  43 st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 14-17, 2003; Chicago, USA.  Poster.
  8. Dugourd D, Brinkman J, Pasetka C, Guarna M, Friedland H, Clement J. Omiganan pentahydrochloride (MBI 226) affects Staphylococcus aureus cell membrane. 43 st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 14-17, 2003; Chicago, USA.  Poster.
  9. Friedland H, Sharp D, Erfle D, Rubinchik E. Omiganan (MBI 226) 1% gel: A novel topical antimicrobial agent with a favorable safety profile.  43 st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 14-17, 2003; Chicago, USA.  Poster.
  10. Hoban D, Witwicki E, Zhanel G, Workman L, Clement J, Friedland H, Dugourd D. In-vitro resistance development of clinically relevant bacteria to omiganan pentahydrochloride. 43 st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept. 14-17, 2003; Chicago, USA.  Poster.
  11. Rubinchik E, McBride J, Liu B, Jiménez E, Workman L, Dugourd  D. In vitro and Ex vivo Antimicrobial Activity of MBI 594AN Against Propionibacterium acnes.  43 rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 14-17, 2003; Chicago, USA.  Poster-E-1706.
  12. Sader H, Rennie R, Brosnikoff C, Gordon K, Jones R. In-vitro activity of omiganan pentahydrochloride, a topical cationic peptide, tested against contemporary bacteria and yeast isolates. 43 rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 14-17, 2003; Chicago, USA.  Poster.
  13. Friedland H, Sharp D, Robinson J. Double-blind, randomized, vehicle-controlled study to asses the safety and efficacy of MBI 594AN in the treatment of acne vulgaris. 61 st Annual Meeting of American Academy of Dermatology; March 21-26, 2003; San Francisco, USA.  Poster-P-51.
  14. Workman L, Fenn J, Tran T, Clement J, Coulson R, Dugourd D. Bactericidal activity and post-antibiotic effect of omiganan pentahydrochloride.   Abstracts of the American Society for Microbiology Northwest Meeting; August 7-10, 2003; Vancouver, Canada.  Poster.
  15. Hoban D, Witwicki E, Zhanel G, Palatnick L, Friedland H, McBride J.  In vitro activity of the novel topical cationic peptide MBI 226 against 750 clinical isolates. 44 th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 3 - Nov. 2, 2004; Washington, USA. Poster-E-1647.
  16. Maki D, Mermel L , McCormick R, Friedland D. Prospective, randomized, investigator-blinded multicenter trial of a novel, topical cationic antimicrobial peptide for prevention of vascular catheter-related infection, Oral presentation: 44 th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Nov. 1, 2004; Washington, USA.
  17. Rennie R, Stevens S, Sader H, Anderegg T, Fritsche T, Jones R.  Susceptibility testing characteristics and quality control guidelines for omiganan pentahydrochloride, a topical cationic peptide. 104 th American Society for Microbiology General Meeting; May 23-27, 2004; New Orleans, USA. Poster-A-132.
  18. Melo M, Castanho M. Biophysical perspective on the preference of Omiganan towards bacterial lipidic membranes over mammalian membranes.   Abstracts of the National Meeting in Biochemistry; October, 2004; Lisbon, Portugal.  Poster.
  19. Melo MN, Castanho M. Omiganan interaction with bacterial membranes. The role of saturation and correlation with clinical properties. 46 th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September, 2006; San Francisco, CA.  Poster.
  20. Isaacson R.  MBI-226 Micrologix/Fujisawa .  Current Opinion in Investigational Drugs. 2003; 4(8):999-1003.
  21. Anderegg, T, Fritsche T, Jones R. Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI 226), a novel antimicrobial peptide.  J Clin. Microbiol. 2004;42:1386-1387.
  22. Sader H, Fedler K, Rennie R, Stevens S, Jones R. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity.   Antimicrob Agents Chemother . 2004;48: 3112-3118.
  23. Melo M., Dugourd D, Castanho M.  Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides.   Recent Patents on Anti-Microbial Drug Discovery , 2006;1:201-207.
  24. Marta Guarna M, Coulson R, Rubinchik E. Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgarus.   FEMS Microbiol Lett. 2006;257(1):1-6.
  25. Fritsche T, Rhomberg P, Sader H, Jones R.  In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate (VISA and hVISA) Staphylococcus aureus.  46 th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 27-39, 2006; San Francisco, CA. Poster-E-1863.
 
 
 
 
 

2007 © Cutanea Life Sciences. All Rights Reserved.
Terms of Use | Sitemap